Avalo Therapeutics, Inc. (AVTX)
NASDAQ: AVTX · Real-Time Price · USD
8.46
-0.27 (-3.09%)
At close: Mar 28, 2025, 4:00 PM
8.52
+0.06 (0.69%)
After-hours: Mar 28, 2025, 7:50 PM EDT
Avalo Therapeutics Revenue
In the year 2024, Avalo Therapeutics had annual revenue of $441.00K, down -77.08%. Avalo Therapeutics had revenue of $192.00K in the quarter ending December 31, 2024, a decrease of -66.37%.
Revenue (ttm)
$441.00K
Revenue Growth
-77.08%
P/S Ratio
84.91
Revenue / Employee
$19,174
Employees
23
Market Cap
90.28M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 441.00K | -1.48M | -77.08% |
Dec 31, 2023 | 1.92M | -16.13M | -89.34% |
Dec 31, 2022 | 18.05M | 12.65M | 234.40% |
Dec 31, 2021 | 5.40M | -1.30M | -19.42% |
Dec 31, 2020 | 6.70M | -51.35K | -0.76% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
AVTX News
- 4 days ago - Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board - GlobeNewsWire
- 5 days ago - Avalo Therapeutics 'Represents An Attractive Pure-Play,' Analyst Initiates Coverage With Over 300% Stock Upside - Benzinga
- 10 days ago - Avalo Reports 2024 Financial Results and Recent Business Updates - GlobeNewsWire
- 4 weeks ago - Avalo Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 7 weeks ago - Avalo Therapeutics to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference - GlobeNewsWire
- 3 months ago - Avalo Therapeutics Appoints Jennifer Riley as Chief Strategy Officer - GlobeNewsWire
- 4 months ago - Avalo Therapeutics Receives $69.4 Million in Proceeds from the Full Exercise of Private Placement Warrants - GlobeNewsWire
- 4 months ago - Avalo Therapeutics to Present at Upcoming Investor Conferences - GlobeNewsWire